Clin2
NCT07400913Possibly a fitNot yet recruiting

Using advanced DNA sequencing to diagnose rare diseases

Rare DiseasesAlbinismIntellectual Disability

Part of Brain & nervous system, Eyes & vision, Genetic & congenital, Hormones & metabolism, Mental health, Skin clinical trials.

This trial uses a new DNA sequencing method that reads long stretches of DNA to find genetic causes of rare diseases. It is for people who have intellectual development disorders or albinism and have not yet gotten a clear genetic diagnosis from standard tests.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
150 people
Ages
Any age
Study type
Observational

Who can take part

  • You must have a sample of your DNA (already stored in the lab) or a frozen blood sample available at the genetics lab.
  • You have a condition that fits one of two groups: a syndromic intellectual development disorder, or albinism (with specific signs like pale skin, nystagmus, or features seen by an eye doctor).
  • If you have intellectual developmental disorder, you must be under 5 years old with severe delays, or 6 years or older with proven intellectual disability along with minor physical signs or organ malformations.
  • If you have albinism, you must have at least two of the listed clinical signs.
  • Standard genetic tests (like panel, exome, or genome sequencing) did not give you a clear answer, or found only one variant in a gene that needs two for the disease.
  • You have not refused participation in research, and you or your legal representative has agreed to this research use of your genetic sample.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07755098Not yet recruiting
New genetic testing for severe developmental disorders

This study uses advanced genetic tests to find the cause of severe intellectual disability or related developmental disorders when standard tests found nothing. If you or your child qualify, the study may provide a clearer diagnosis and help guide care.

Dijon
NCT05046444Recruiting
Testing tricky blood cancer diagnoses with advanced DNA sequencing

This study uses advanced DNA sequencing to figure out unclear or unusual blood (hematologic) conditions when standard tests are not enough. It may help your care team reach a more accurate diagnosis by better understanding what’s driving your illness.

Munich
NCT06796751Recruiting
Better DNA testing for unclear genetic results

This study uses a new, advanced DNA sequencing method (long-read sequencing) to try to clarify unclear or incomplete genetic test results. If you or a family member have had genetic testing that left unanswered questions, this trial may help find more definite answers.

Bologna, Bologna
NCT04024774Recruiting
Genetic testing study for rare diseases with an unclear cause

This study looks for a genetic (DNA) explanation for rare diseases when usual genetic testing hasn’t found an answer. It may help by re-analyzing prior results and comparing them with parents’ DNA to better pinpoint the cause.

Dijon
NCT07665554Not yet recruiting
Long-read sequencing for neurogenetic diagnoses

This study uses advanced long-read DNA sequencing to find hidden genetic causes of neurological diseases. It may help people who have a known repeat expansion or those with an unexplained neurological condition and willing family members.

Bordeaux, France
NCT01087320Recruiting
Genetic testing study to find causes of rare disorders

This study uses genome (DNA) sequencing to look for the genetic cause of rare disorders, especially when the cause is unknown. It may help some families better understand what is driving the condition, using genetic information from the affected person and often their parents.

Bethesda, Maryland

Hear when a new Rare Diseases trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.